Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

Emerging Infectious Diseases

Volumn 15, Issue 8, 2009, Pages 1206-1213

  Mooi, Frits R ^a   Van Loo, Inge H M ^b   Van Gent, Marjolein ^a   He, Qiushui ^c   Bart, Marieke J ^a   Heuvelman, Kees J ^a   De Greeff, Sabine C ^a   Diavatopoulos, Dimitri ^a   Teunis, Peter ^a   Nagelkerke, Nico ^d   Mertsola, Jussi ^e  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; INFECTION CONTROL; NETHERLANDS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERTUSSIS; PROMOTER REGION; VACCINATION;

ADOLESCENT; ALLELES; BACTERIAL OUTER MEMBRANE PROTEINS; BASE SEQUENCE; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES, EMERGING; DNA PRIMERS; DNA, BACTERIAL; GENES, BACTERIAL; HUMANS; INFANT; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; NETHERLANDS; PERTUSSIS TOXIN; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEQUENCE HOMOLOGY, NUCLEIC ACID; VIRULENCE; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH; YOUNG ADULT;

EID: 68049114693     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1508.081511     Document Type: Article

References (38)

1. Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: Saunders; 2004. p. 471-528.
2. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis. 2003;3:413-8. DOI: 10.1016/S1473-3099(03)00669-8
3. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6:348-57.
4. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(Suppl):S104-8. DOI: 10.1097/01. inf.0000166154.47013.47
5. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006;53:106-13. DOI: 10.1016/j.jinf.2005.10.020
6. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115:1422-7. DOI: 10.1542/peds.2004- 2648
7. Halperin SA. The control of pertussis - 2007 and beyond. N Engl J Med. 2007;356:110-3. DOI: 10.1056/NEJMp068288
8. Mooi FR, He Q, Guiso N. Phylogeny, evolution, and epidemiology of Bordetellae. In: Locht C, editor. Bordetella molecular microbiology, 1st ed. Norfolk (UK): Horizon Bioscience; 2007. p. 17-45.
9. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66:670-5.
10. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the wholecell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine. 2004;22:2122-8. DOI: 10.1016/j. vaccine.2003.12.006
11. Fingermann M, Fernandez J, Sisti F, Rodriguez ME, Gatti B, Bottero D, et al. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine. 2006;24:3513-21. DOI: 10.1016/j.vaccine.2006.02.026
12. Watanabe M, Nagai M. Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection. J Health Sci. 2002;48:560-4. DOI: 10.1248/ jhs.48.560
13. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology. 2001;147:2885-95.
14. Verwey W, Thiele E, Sage D, Suchardt L. A simplified liquid culture medium for the growth of Haemophilus pertussis. J Bacteriol. 1949;58:127-34.
15. Hijnen M, He Q, Schepp R, van Gageldonk P, Mertsola J, Mooi FR, et al. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis. 2008;40:94-104. DOI: 10.1080/00365540701642138
16. Bartoloni A, Pizza M, Bigio M, Nucci D, Ashworth LA, Irons LI, et al. Mapping of a protective epitope of pertussis toxin by in vitro refolding of recombinant fragments. Bio/Technology. 1988;6:709-12. DOI: 10.1038/nbt0688-709
17. Hewlett EL, Donato GM. Bordetella toxins. In: Locht C, editor. Bordetella molecular microbiology. Norfolk (UK): Horizon Bioscience; 2007. p. 97-118.
18. Stibitz S. The bvg regulon. In: Locht C, editor. Bordetella molecular microbiology. Norfolk (UK): Horizon Bioscience; 2007. p. 47-67.
19. van Loo IH, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol. 2002;40:1994-2001. DOI: 10.1128/JCM.40.6.1994-2001.2002
20. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog. 2005;1:e45. DOI: 10.1371/journal. ppat.0010045
21. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica. Nat Genet. 2003;35:32-40. DOI: 10.1038/ng1227
22. Hallander H, Advani A, Riffelmann M, vonKonig CHW, Caro V, Guiso N, et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol. 2007;45:3257-62. DOI: 10.1128/JCM.00864-07
23. Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, He Q, et al. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine. 2007;25:918-26. DOI: 10.1016/j.vaccine.2006.09.012
24. Carbonetti NH, Artamonova GV, Van Rooijen N, Ayala VI. Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun. 2007;75:1713-20. DOI: 10.1128/IAI.01578-06
25. Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest. 2005;115:3594-601. DOI: 10.1172/JCI24609
26. Mielcarek N, Riveau G, Remoue F, Antoine R, Capron A, Locht C. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat Biotechnol. 1998;16:454-7. DOI: 10.1038/nbt0598-454
27. King AJ, van Gorkom T, Pennings JL, van der Heide HG, He Q, Diavatopoulos D, et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics. 2008;9:311. DOI: 10.1186/1471-2164-9-311
28. Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Ther. 2004;2:447-54. DOI: 10.1586/14787210.2.3.447
29. Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med. 2000;26:1512-4. DOI: 10.1007/s001340000587
30. Advani A, Gustafsson L, Carlsson RM, Donnelly D, Hallander HO. Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS. 2007;115:736-42. DOI: 10.1111/j.1600-0463.2007.apm-628.x
31. Van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol Infect. 1999;123:403-11. DOI: 10.1017/ S0950268899003052
32. Preziosi MP, Yam A, Wassilak SG, Chabirand L, Simaga A, Ndiaye M, et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol. 2002;155:891-6. DOI: 10.1093/aje/155.10.891
33. Davison F, Nair V. Use of Marek's disease vaccines: could they be driving the virus to increasing virulence? Expert Rev Vaccines. 2005;4:77-88. DOI: 10.1586/14760584.4.1.77
34. Best SM, Kerr PJ. Coevolution of host and virus: the pathogenesis of virulent and attenuated strains of myxoma virus in resistant and susceptible European rabbits. Virology. 2000;267:36-48. DOI: 10.1006/viro.1999.0104
35. Mackinnon MJ, Read AF. Immunity promotes virulence evolution in a malaria model. PLoS Biol. 2004;2:E230. DOI: 10.1371/journal. pbio.0020230
36. Gandon S, Mackinnon MJ, Nee S, Read AF. Imperfect vaccines and the evolution of pathogen virulence. Nature. 2001;414:751-6. DOI: 10.1038/414751a
37. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergard T, et al. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis. 2001;33:1004-10. DOI: 10.1086/322639
38. Luttinger P. The epidemiology of pertussi. Am J Dis Child. 1916;12:290-315.